AnPac Bio-Medical: Jumps on securing $8 mln funding in China
** U.S.-listed shares of Chinese biotech co ANPC.O rise
7.6% to $4.09 premarket
* ANPC says it secured three grants and one rental award in
China; total funding amount ~$8 mln urn:newsml:reuters.com:*:nGNX6BtnwM
** Grant and award payments expected to be received over a
few years starting this qtr and will help in funding R&D and new
product commercialization - ANPC
** ANPC has two certified clinical labs in China and one in
U.S., where it performs a suite of cancer screening and
detection tests
** Stock down 66% YTD since Jan. 30 IPO
(Reporting By Mrinalika Roy in Bengaluru)
((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))
Recent news on Fresh2
See all newsBrief: Fresh2 Group On Dec 20, Received Nasdaq Notice That It Will Be Delisted From Nasdaq Capital Market Effective At Open Of Market On Dec 24
Brief: Fresh2 Group Ltd. Announces Receipt Of Staff Delisting Determination From Nasdaq Intends To Request A Hearing
Brief: Fresh2 Group Ltd Announces Receipt Of A Delinquency Compliance Alert Notice From Nasdaq
Brief: Anpac Bio-Medical Science - In Dec 2022 And Jan 2023, Signed Definitive Investment Agreements With Several Third Party Investors
Brief: AnPac Bio Granted Continued Listing By Nasdaq Hearing Panel, Subject To Meeting $1 Bid Price Compliance Rule On Or Before Nov. 23, 2022